• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Edges Lower; Asensus Surgical Shares Jump

    6/7/24 3:05:33 PM ET
    $ASXC
    $BMEA
    $BNED
    $GERN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASXC alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Friday.

    The Dow traded up 0.12% to 38,931.98 while the NASDAQ fell 0.09% to 17,156.98. The S&P 500 also rose, gaining, 0.11% to 5,359.05.

    Check This Out: Vail Resorts, DocuSign And 3 Stocks To Watch Heading Into Friday

    Leading and Lagging Sectors

    Financial shares climbed by 0.7% on Friday.

    In trading on Friday, real estate shares dipped by 0.8%.

    Top Headline

    The total number of active U.S. oil rigs fell by four to 492 rigs this week, Baker Hughes Inc reported.

    Equities Trading UP
                           

    • Venus Concept Inc. (NASDAQ:VERO) shares shot up 74% to $1.0776 on continued upward momentum after the stock regained Nasdaq compliance.
    • Shares of Asensus Surgical, Inc. (NYSE:ASXC) got a boost, surging 41% to $0.3322 after the company announced it will be acquired by KARL STORZ for $0.35 per share in cash.
    • Geron Corporation (NASDAQ:GERN) shares were also up, gaining 20% to $4.6650. On Thursday, the FDA approved Geron's Rytelo (imetelstat) for adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.

    Equities Trading DOWN

    • Biomea Fusion, Inc. (NASDAQ:BMEA) shares dropped 64% to $4.07 after the United States Food and Drug Administration (FDA) imposed a full clinical hold on its Phase I/II trials for BMF-219, a diabetes treatment.
    • Shares of Barnes & Noble Education, Inc (NYSE:BNED) were down 43% to $0.1856 after the company announced final results of rights offering.
    • GameStop Corp. (NYSE:GME) was down, falling 41% to $27.45 after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares.

    Also Check This Out: Top 3 Energy Stocks That May Fall Off A Cliff In Q2

    Commodities

    In commodity news, oil traded down 0.2% to $75.38 while gold traded down 3.1% at $2,317.60.

    Silver traded down 6.6% to $29.29 on Friday, while copper fell 4.4% to $4.4715.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.22%, Germany's DAX declined 0.51% and France's CAC 40 fell 0.48%. Spain's IBEX 35 Index fell 0.34%, while London's FTSE 100 fell 0.48%.

    The Eurozone economy grew by 0.3% on quarter during the first three months of the year, compared to a 0.1% contraction in each of the prior two quarters. The Halifax House Price Index in the UK gained 1.5% year-over-year in May following a 1.1% increase in April.

    French trade deficit increased to €7.6 billion in April, compared to market estimates of €5.4 billion. German trade surplus narrowed to EUR 22.1 billion in April versus a revised EUR 22.2 billion in March. Exports from Germany rose by 1.6% month-over-month to a 14-month high level of EUR 136.5 billion in April, while imports to Germany rose by 2.0% to a 10-month high of EUR 114.5 billion.

    Asia Pacific Markets

    Asian markets closed mixed on Friday, with Japan's Nikkei falling 0.05%, China's Composite Index gaining 0.08%, Hong Kong's Hang Seng Index dipping 0.59% and India's S&P BSE Sensex gaining 2.16%.

    Foreign exchange reserves in Singapore rose to SGD 500.86 billion in May versus SGD 500.30 billion in the prior month, while China’s foreign exchange reserves climbed to $3.23 trillion in May from $3.2 trillion a month ago. China’s trade surplus increased to $82.62 billion in May from $65.55 billion in the year-ago period.

    The index of leading economic indicators in Japan fell to 111.6 in April versus a revised 111.7 in the prior month, while index of coincident economic indicators rose to 115.2 in April from a revised 114.2 in the previous month. The Reserve Bank of India maintained its benchmark policy repo at 6.5% in June.

    Economics

    • U.S. nonfarm payrolls increased by 272,000 in May, a slowdown from April's 165,000 and far more than the 180,000 increase anticipated by Econoday.
    • The unemployment rate inched higher from 3.9% to 4%. Average hourly earnings rose by 4.1% year-over-year, up from 3.9% in April and below the expected 3.9% increase.
    • U.S. wholesale inventories increased by 0.1% month-over-month in April compared to the advance reading of a 0.2% increase and versus a revised 0.5% declined in the previous month.
    • The total number of active U.S. oil rigs fell by four to 492 rigs this week, Baker Hughes Inc reported.

    Now Read This: Wall Street’s Most Accurate Analysts Weigh In On 3 Risk Off Stocks Delivering High-Dividend Yields

    Get the next $ASXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASXC
    $BMEA
    $BNED
    $GERN

    CompanyDatePrice TargetRatingAnalyst
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    Biomea Fusion Inc.
    $BMEA
    8/28/2025$5.00Buy
    Jefferies
    Geron Corporation
    $GERN
    7/10/2025$1.00Sell
    Goldman
    Biomea Fusion Inc.
    $BMEA
    6/3/2025$7.00Overweight
    Piper Sandler
    Geron Corporation
    $GERN
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    Geron Corporation
    $GERN
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    Geron Corporation
    $GERN
    2/26/2025Buy → Neutral
    H.C. Wainwright
    Geron Corporation
    $GERN
    11/5/2024$8.00Buy
    H.C. Wainwright
    More analyst ratings

    $ASXC
    $BMEA
    $BNED
    $GERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Erdtmann Rainer M decreased direct ownership by 21% to 572,427 units (SEC Form 5)

    5 - Biomea Fusion, Inc. (0001840439) (Issuer)

    2/6/26 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $ASXC
    $BMEA
    $BNED
    $GERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Biomea Fusion with a new price target

    Rodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00

    1/13/26 10:18:10 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Biomea Fusion with a new price target

    Jefferies initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $5.00

    8/28/25 8:09:13 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Geron with a new price target

    Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00

    7/10/25 8:55:29 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $BMEA
    $BNED
    $GERN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    6/7/24 12:36:59 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $BMEA
    $BNED
    $GERN
    SEC Filings

    View All

    SEC Form EFFECT filed by Venus Concept Inc.

    EFFECT - Venus Concept Inc. (0001409269) (Filer)

    2/11/26 12:15:13 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Venus Concept Inc.

    EFFECT - Venus Concept Inc. (0001409269) (Filer)

    2/11/26 12:15:14 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Venus Concept Inc.

    EFFECT - Venus Concept Inc. (0001409269) (Filer)

    2/11/26 12:15:17 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $ASXC
    $BMEA
    $BNED
    $GERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ASXC
    $BMEA
    $BNED
    $GERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Director Attal Alain bought $259,577 worth of shares (12,000 units at $21.63), increasing direct ownership by 2% to 596,464 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/21/26 6:32:09 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.c

    2/11/26 7:27:26 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barnes & Noble Education Reports First Half Fiscal 2026 Results and Files Related Quarterly Reports

    BNC First Day Program Revenue Increases 29.0% in 26 weeks ended November 1, 2025 Net Income Improves to $6.7 million Company Reports Total Net Debt of $110.8 million as of November 1, 2025, a $55.1 million Decline Year-Over-Year Reiterates Prior Fiscal 2026 Outlook, including $65-$75 million in Adjusted EBITDA FLORHAM PARK, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE:BNED), ("Barnes & Noble Education," "BNED," "the Company," "we," "us," "our"), a leading solutions provider for the education industry, today announced that it has filed its Quarterly Report on Form 10-Q for the fiscal quarters ended August 2, 2025 and November 1, 2025. With these filings,

    1/20/26 8:00:00 AM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Cineverse and GameStop Invite Fans to 'Return to Silent Hill' with Innovative Partnership featuring Mysterious Messages, Exclusive Rewards, In-Store Media & More

    Return to Silent Hill Hits Theaters Nationwide on January 23 – Buy Tickets Now LOS ANGELES and GRAPEVINE, Texas, Jan. 14, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), a next generation entertainment studio, and GameStop Corp. (NYSE:GME), are pulling out all the stops in anticipation of the January 23 wide theatrical release of Return to Silent Hill (returntosilenthillmovie.com).  The two companies are collaborating on an immersive marketing campaign for the new film, based on the visionary video game, SILENT HILL 2. Since January 7, fans who visit a participating GameStop ca

    1/14/26 3:02:00 PM ET
    $CNVS
    $GME
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Electronics Distribution

    $ASXC
    $BMEA
    $BNED
    $GERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Barnes & Noble Education Inc

    SC 13G/A - Barnes & Noble Education, Inc. (0001634117) (Subject)

    11/14/24 6:34:18 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 5:46:12 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 9:31:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $BMEA
    $BNED
    $GERN
    Financials

    Live finance-specific insights

    View All

    Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.c

    2/11/26 7:27:26 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis Strengthened leadership team with appointment of Chief Commercial Officer and additional key executives Announced one oral and four poster presentations accepted at the American Society of Hematology (ASH) 2025 Annual Meeting  Company to host conference call and webcast today, November 5, at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 an

    11/5/25 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

    Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website. About Geron Geron is a com

    10/27/25 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $BMEA
    $BNED
    $GERN
    Leadership Updates

    Live Leadership Updates

    View All

    Cineverse and GameStop Invite Fans to 'Return to Silent Hill' with Innovative Partnership featuring Mysterious Messages, Exclusive Rewards, In-Store Media & More

    Return to Silent Hill Hits Theaters Nationwide on January 23 – Buy Tickets Now LOS ANGELES and GRAPEVINE, Texas, Jan. 14, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), a next generation entertainment studio, and GameStop Corp. (NYSE:GME), are pulling out all the stops in anticipation of the January 23 wide theatrical release of Return to Silent Hill (returntosilenthillmovie.com).  The two companies are collaborating on an immersive marketing campaign for the new film, based on the visionary video game, SILENT HILL 2. Since January 7, fans who visit a participating GameStop ca

    1/14/26 3:02:00 PM ET
    $CNVS
    $GME
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Electronics Distribution

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Geron Corporation Announces Executive Leadership Transitions and Appointments

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2012 and has served as Executive Vice President, Chief Operating Officer since January 2019, will depart the company on October 15, 2025, transitioning to a consulting role, while pursuing other interests. Jim Ziegler, who joined the company in September 2024 as Executive Vice President, Chief Commer

    10/13/25 4:34:48 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care